The European Medicines Agency's Committee For Medicinal Products For Human Use Has Adopted A Positive Opinion Recommending Gilead Sciences' Trodelvy (Sacituzumab Govitecan) As Monotherapy In Pre-Treated HR+/HER2- Metastatic Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended Gilead Sciences' Trodelvy for pre-treated HR+/HER2- metastatic breast cancer.
June 23, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gilead Sciences' Trodelvy receives positive recommendation from EMA committee for pre-treated HR+/HER2- metastatic breast cancer.
The positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use is a significant step towards the approval of Trodelvy in Europe. This could lead to increased sales and revenue for Gilead Sciences, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100